Oculis Holding AG
OCS
Company Profile
Business description
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Contact
Bahnhofstrasse 20
ZugCH-6300
CHET: +41 417113960
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
Shares leap for ASX rare earths provider
We increased our fair value based on higher expected rare earths pricing.
stocks
Does SpaceX’s sky-high valuation make sense?
SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,851.40 | 29.00 | -0.33% |
| CAC 40 | 7,984.44 | 57.37 | -0.71% |
| DAX 40 | 23,589.65 | 50.38 | -0.21% |
| Dow JONES (US) | 46,853.61 | 563.66 | -1.19% |
| FTSE 100 | 10,264.71 | 89.06 | -0.86% |
| HKSE | 25,716.76 | 182.00 | -0.70% |
| NASDAQ | 22,405.63 | 310.50 | -1.37% |
| Nikkei 225 | 54,452.96 | 572.41 | -1.04% |
| NZX 50 Index | 13,199.29 | 93.84 | -0.71% |
| S&P 500 | 6,697.10 | 78.70 | -1.16% |
| S&P/ASX 200 | 8,629.00 | 14.20 | -0.16% |
| SSE Composite Index | 4,129.10 | 4.33 | -0.10% |